Ibrutinib resistance mutations often arise early, suggesting potential as a cue for alternative therapy

Ibrutinib resistance mutations often arise early, suggesting potential as a cue for alternative therapy

Mutations in two genes often occurred months before relapse of chronic lymphocytic leukemia (CLL) treated with ibrutinib (Imbruvica), suggesting potential as a cue for alternative therapy, according to a retrospective review of four clinical trials.

Among patients who had CLL relapse, acquired mutations in BTK and PLCG2 occurred in 85% of cases. The mutations arose a median of 9.3 months prior to overt disease relapse, reported Jennifer A. Woyach, MD, of Ohio State University in Columbus, and colleagues.

medpagetoday.com/Hematology...

Neil

Photo: Seal Pup at Seal Bay, Kangaroo Island

5 Replies

oldestnewest
  • Even if the mutations are found early are there other treatments besides the ones we know about to deal with this? Isn't it still a choice of fcr br or idela or obin or venetoclax? Do we know which of these address certain mutations better than others?

  • No ... very early days on these mutations... still in the lab...

    Still trying to expand the knowledge base...

    ~chris

  • Great photo - pure eye candy - thank your!

  • I see I've doubled up on an earlier posting by Cllcanada that can be found here: healthunlocked.com/cllsuppo...

  • Thank you for a good article. I was treatment naïve now On imbruvica and will add Veneticlax soon but 17 P deleted so I will need to watch for this. I am on a clinical trial. Hopefully the combo therapy will knock down the disease so much that this will not be in issue.

    It is good to know it can be seen early.

You may also like...